<DOC>
	<DOCNO>NCT01274403</DOCNO>
	<brief_summary>The aim study compare efficacy toxicity melphalan prednisone versus meplhalan , prednisone Thalidomide elderly patient multiple myeloma patient multiple myeloma eligible high dose treatment stem cell support .</brief_summary>
	<brief_title>A Randomized Study With Oral Melphalan + Prednisone ( MP ) Versus Melphalan , + Prednisone + Thalidomide ( MPT ) Newly Diagnosesd Elderly Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>newly diagnose multiple myeloma . Age &gt; 65 year ECOG &lt; = 3 Written informed consent give time randomization Patients age &lt; = 65 eligible high dose treatment stem cell support ECOG &gt; 3 current neoplasm.. contraindication use thalidomide peripheral neurophaty</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Elderly patient</keyword>
</DOC>